- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00312962
Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia (CRIS)
Neuroscience-Guided Remediation of Cognitive Deficits in Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Schizophrenia is a chronic brain disorder that causes severe disability. It is characterized by psychotic symptoms, including hallucinations and delusions. Neurocognitive deficits, such as impaired neurocognitive processing efficiency, also affect people with schizophrenia. This deficiency in the speed and accuracy with which the brain perceives and responds to targets causes scrambled messages to be transmitted in the brain, thereby affecting executive control and memory. Medications are available that effectively treat the psychotic symptoms. The neurocognitive deficits, however, do not subside with medication treatment, and are responsible for the failure to improve the e their psychosocial functioning of people with schizophrenia, even after their psychotic symptoms have gone into remission. The targeted cognitive training (TCT) exercises in this study are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets. This study will determine the effectiveness of reward-intensive, computer-based TCT in improving neurocognitive deficits in people with schizophrenia.
Participants in this double-blind study will be paired according to IQ and baseline symptom severity. One member of each pair will be randomly assigned to training exercises that use TCT. The other will be assigned to a control intervention, which will involve commercially available computer games. All participants will complete exercises with their assigned intervention for 1 hour per day, 5 days per week, until 90 hours of training has been accumulated. Neuroimaging will be performed on a subgroup of participants to examine changes in brain activation patterns in response to the cognitive training. Upon study completion and at the 6-month follow up visit, participants will be assessed for improvement in the following areas: cognitive performance; symptom profile; quality of life; and social cue recognition.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- San Francisco Department of Veterans Affairs Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder
- Good general health
- First language is English
- Clinically stable (i.e., no inpatient hospital stays for 3 months prior to study entry; on stable doses of medication)
Exclusion Criteria:
- History of substance abuse within 6 months prior to study entry
- Neurological disorder
- Any metal in the body, or claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1
Participants will use commercially available computer games
|
The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
|
|
Experimental: 2
Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
|
TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks.
TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cognitive performance as measured by a neuropsychological battery
Time Frame: Measured at Weeks 8, 14, and 8 and Month 6 follow-up
|
Measured at Weeks 8, 14, and 8 and Month 6 follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Symptom profile as measured by clinical interviews
Time Frame: Measured at Weeks 8, 14, and 8 and Month 6 follow-up
|
Measured at Weeks 8, 14, and 8 and Month 6 follow-up
|
|
Quality of life as measured by clinical interviews
Time Frame: Measured at Weeks 8, 14, and 8 and Month 6 follow-up
|
Measured at Weeks 8, 14, and 8 and Month 6 follow-up
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sophia Vinogradov, MD, UCSF, SFVAMC, NCIRE
Publications and helpful links
General Publications
- Puig O, Fisher M, Loewy R, Miley K, Ramsay IS, Carter CS, Ragland JD, Niendam T, Vinogradov S. Early- Versus Adult-Onset Schizophrenia as a Predictor of Response to Neuroscience-Informed Cognitive Training. J Clin Psychiatry. 2020 Mar 3;81(2):18m12369. doi: 10.4088/JCP.18m12369.
- Panizzutti R, Hamilton SP, Vinogradov S. Genetic correlate of cognitive training response in schizophrenia. Neuropharmacology. 2013 Jan;64(1):264-7. doi: 10.1016/j.neuropharm.2012.07.048. Epub 2012 Aug 7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MH068725 (U.S. NIH Grant/Contract)
- DATR A2-AISZ (World Health Organization ICTRP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
-
Central Institute of Mental Health, MannheimRecruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
Clinical Trials on Computer games
-
Kocaeli Sağlık ve Teknoloji ÜniversitesiNot yet recruitingSatisfaction, Self-regulation, Injection SkillsTurkey (Türkiye)
-
University of AlbertaCompletedDementia | Alzheimer Disease | Healthy Aging | Mild Cognitive Impairment | Cognitive DeclineCanada
-
Beth Israel Deaconess Medical CenterNational Institute of Mental Health (NIMH)Completed
-
University of California, San FranciscoNational Institute of Mental Health (NIMH)CompletedSchizophreniaUnited States
-
University of California, San FranciscoStanley Medical Research InstituteCompletedSchizophreniaUnited States
-
National Healthcare Group, SingaporeCompleted
-
Shalvata Mental Health CenterCompletedDepression | Anxiety | ADHD | PDD | ConductIsrael
-
University of CalgaryNational Alliance for Research on Schizophrenia and DepressionCompletedProdromal Schizophrenia
-
University of Southern CaliforniaCompletedLow Executive Function in ChildrenUnited States
-
University of Texas at AustinCompletedMultiple SclerosisUnited States